



Review



The *Streptomyces* Genome and Its Exceptional Capacity for Antibiotics Production

Emily W. T. Tam¹, Susanna K. P. Lau² and Patrick C. Y. Woo^{3,4,*}

1 School of Science and Technology, Hong Kong Metropolitan University, Ho Man Tin, Kowloon, Hong Kong, China

2 Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China

3 Doctoral Program in Translational Medicine and Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan

4 The iEGG and Animal Biotechnology Research Center, National Chung Hsing University, Taichung 402, Taiwan

* Correspondence: pcywoo@hku.hk

How To Cite: Tam, E.W.T.; Lau, S.K.P.; Woo, P.C.Y. The *Streptomyces* Genome and Its Exceptional Capacity for Antibiotics Production. *Natural Products Analysis* 2026, 2(1), 100005. <https://doi.org/10.53941/npa.2026.100005>

Received: 26 February 2026

Revised: 9 April 2026

Accepted: 10 April 2026

Published: 23 April 2026

Abstract: If bacteria are ranked by the number of commercially available antibiotics produced, *Streptomyces* would be number one by an overwhelming margin—producing more approved drugs than all other bacterial genera combined. *Streptomyces* is a group of filamentous, Gram-positive, soil-dwelling bacteria. *Streptomyces* species possess large (7–12 Mb) genomes, significantly larger than those of most other bacteria. Many species also carry large linear plasmids. The hallmark of *Streptomyces* genomics is the presence of numerous secondary metabolite biosynthetic gene clusters (BGCs), one of the most critical reasons for *Streptomyces* species having an exceptional capacity for antibiotics production. Each cluster contains a co-localized set of genes responsible for the biosynthesis, tailoring, regulation, resistance, and transport of a specific secondary metabolite. Major BGC types include polyketide synthase (PKS) clusters, non-ribosomal peptide synthase (NRPS) clusters, hybrid PKS-NRPS clusters, ribosomally synthesized and post-translationally modified peptide clusters, and terpene and siderophore clusters; and the most important classes and prototype examples of antibiotics produced include aminoglycosides (e.g., streptomycin, neomycin, kanamycin, tobramycin), polyketides (e.g., erythromycin, tetracycline, rifampicin), non-ribosomal peptides (e.g., vancomycin, teicoplanin, daptomycin), chloramphenicol, and β -lactam (cephamycins, clavulanic acid, thienamycin, imipenem). Most antibiotic-producing *Streptomyces* species encode self-resistance genes within or near the BGC, ensuring that antibiotic production does not harm the producing organism. Advancement of technologies, such as next-generation sequencing, robust bioinformatics tools, and artificial intelligence-based methods, could reveal the hidden or silent BGCs and enable genome mining, activation of silent pathways and discovery of entirely new antibiotics in *Streptomyces* that traditional methods would miss.

Keywords: *Streptomyces*; genome; antibiotic

1. Introduction

Antibiotics are among the most important therapeutic agents in modern medicine, used to treat and prevent bacterial infections in humans, animals, and to a lesser extent, plants. Since the discovery of penicillin in the early twentieth century, a wide variety of antibiotics have been developed and commercialized [1]. Although antibiotics differ greatly in their chemical structures, mechanism of action, and spectra of activity, they can be broadly



Copyright: © 2026 by the authors. This is an open access article under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Publisher's Note: Scilight stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

classified according to their sources, which include natural biological sources (e.g., penicillin from *Penicillium chrysogenum*), semi-synthetic modification of natural compounds (e.g., doxycycline, synthetically derived from oxytetracycline, a naturally occurring tetracycline produced by *Streptomyces* species), and fully synthetic chemical processes (e.g., ciprofloxacin, through synthetic organism chemistry, often starting with 2,4-dichloro-5-fluorobenzoyl chloride or similar quinoline derivatives). The natural biological compounds are from either bacterial or fungal sources; and many of the earliest and most important antibiotics are derived from their soil-dwelling species [2]. These microorganisms naturally produce antimicrobial compounds to compete with other microbes in their environment [3–5].

One of the most significant bacterial genera in antibiotic production is *Streptomyces*, a group of filamentous, Gram-positive bacteria (“strepto” = twisted, “myces” = fungus). It was named as such because it grew in branching filaments like fungal hyphae. If bacteria are ranked by the number of commercially available antibiotics, *Streptomyces* would be number one by an overwhelming margin—producing more approved drugs than all other bacterial genera combined (Figure 1) [6]. These natural antibiotics are typically produced commercially through industrial fermentation, in which the bacteria are grown in large bioreactors under controlled conditions to maximize antibiotic yield. Among various reasons, one of the most critical is that *Streptomyces* species have an exceptional capacity for antibiotic production, owing to their large genomes and the high number of secondary metabolite biosynthetic gene clusters (BGCs) they encode [7–10]. In this article, we review the basic genomics of *Streptomyces*, with particular reference to the different types of BGCs for antibiotic production, as well as some prototype examples synthesized by these BGCs. Antibiotics produced by a *Streptomyces* species when it was discovered, but the bacterium was subsequently reclassified into another genus, are also included. For example, rifamycin B and vancomycin were originally discovered from *S. mediterranei* and *S. orientalis*, respectively, which were subsequently reclassified and renamed as *Amycolatopsis rifamycinica* and *Amycolatopsis orientalis*, respectively [11–15].




Figure 1. Clinically important antibiotics discovered from *Streptomyces* species during the “golden age” (1940s–1980s) [16–29].

2. The *Streptomyces* Genome

Streptomyces species possess large bacterial genomes, typically ranging from 7 to 12 megabases, significantly larger than those of many other bacteria (e.g., *Escherichia coli* has a genome size of around 4.6 Mb) [7–9]. The G+C content is high, typically around 70–73%. Although this can impose metabolic costs, it may also facilitate the evolution of complex enzymatic systems such as polyketide synthases (PKSs) and non-ribosomal peptide

synthases (NRPSs), which require large, repetitive gene sequences that benefit from genome stability [30,31]. A distinctive feature of *Streptomyces* genomes is their linear chromosome, which is rare among bacteria [32]. This linear chromosome is capped by terminal inverted repeats and covalently bound terminal proteins that protect chromosome ends. In addition to the main chromosome, many species also carry large linear plasmids, which often encode secondary metabolite BGCs [33,34]. The chromosome itself is functionally compartmentalized into a central core region and variable arms at both ends [35]. The central core region is highly conserved across species and contains essential housekeeping genes, whereas the variable arms are enriched in secondary metabolism genes, mobile elements, and horizontally acquired DNA. This organization allows *Streptomyces* to maintain core cellular functions while rapidly evolving specialized metabolic traits.

The hallmark of *Streptomyces* genomics is the presence of numerous BGCs (Table 1). A single *Streptomyces* genome typically encodes 20–40 BGCs, and in some cases even more [7,36]. Each cluster contains a co-localized set of genes responsible for the biosynthesis, tailoring, regulation, resistance, and transport of a specific secondary metabolite. Major BGC types include PKS clusters, NRPS clusters, hybrid PKS-NRPS clusters, ribosomally synthesized and post-translationally modified peptide clusters, and terpene and siderophore clusters [37]. Interestingly, many of these clusters are silent or poorly expressed under standard laboratory conditions, suggesting that *Streptomyces* has far greater biosynthetic potential than is currently observed [38,39]. Most antibiotic-producing *Streptomyces* species encode self-resistance genes within or near the BGC [40]. These may include drug-modifying enzymes, target-modified variants, essential proteins, or efflux pumps. This tight genetic linkage ensures that antibiotic production does not harm the producing organism; while at the same time, they may also serve as a source of resistance if they are transferred to other bacteria [41]. This co-localization strongly supports the idea that antibiotics evolved primarily as ecological tools rather than as metabolic by-products [42].

Table 1. Examples of antibiotic biosynthetic pathways in *Streptomyces*.

Biosynthetic Pathway	Biosynthetic Mechanism	Example Antibiotic(s)	Producing <i>Streptomyces</i> Species (or Former <i>Streptomyces</i>)	Antibiotic Class and Mechanism of Action	References
Aminoglycoside	Sugar biosynthesis & linkage: Utilizes specialized glycosyltransferases, aminotransferases, and oxidoreductases to synthesize and link modified amino-sugars (aminocyclitols).	Streptomycin Neomycin Kanamycin Tobramycin	<i>S. griseus</i> <i>S. fradiae</i> <i>S. kanamyceticus</i> <i>S. tenebrarius</i>	Aminoglycosides: Broad-spectrum antibiotics that bind to the 30S ribosomal subunit and induce codon misreading.	[43–49]
Type I PKS	Modular assembly line: Giant multi-domain enzymes sequentially add and modify short-chain carboxylic acids (e.g., malonyl-CoA).	Erythromycin Rifampicin	<i>S. erythreus</i> * <i>S. mediterranei</i> *	Macrolides (Erythromycin): Bind to the 50S ribosomal subunit to inhibit protein synthesis. Ansamycins (Rifampicin): Inhibits bacterial DNA-dependent RNA polymerase.	[13,50–54]
Type II PKS	Iterative complex: A single set of discrete enzymes iteratively builds a highly reactive poly-beta-ketone chain, which is then folded and cyclized into rigid ring systems.	Tetracycline	<i>S. aureofaciens</i>	Tetracyclines: Broad-spectrum antibiotics that inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit.	[16,55–58]
NRPS	Modular assembly line: Similar to Type I PKS, but links amino acids (including non-proteinogenic and D-amino acids) into highly modified peptide chains independently of ribosomes.	Vancomycin Daptomycin	<i>S. orientalis</i> * <i>S. roseosporus</i>	Glycopeptides (Vancomycin): Inhibit cell wall synthesis by binding to the D-ala-D-ala terminus. Cyclic lipopeptides (Daptomycin): Disrupt Gram-positive bacterial cell membranes.	[17,18,59–67]
Chloramphenicol	Shikimate pathway derivative: Synthesized from chorismate via a specialized non-ribosomal branch. Involves unique enzymes like arylamine N-acetyltransferases and halogenases to form its dichloroacetyl and nitro groups.	Chloramphenicol	<i>S. venezuelae</i>	Amphenicols: Broad-spectrum antibiotics that inhibit protein synthesis by binding to the peptidyl transferase center of the 50S ribosomal subunit.	[19,68–72]
β -lactams (NRPS-like)	Peptide condensation & cyclization: Non-ribosomal peptide synthetases (e.g., ACV synthetase) condense amino acids (like L- α -amino adipic acid, L-cysteine, D-valine), followed by cyclization (e.g., by isopenicillin N synthase) to form the β -lactam ring.	Cephamecins Clavulanic acid Thienamycin	<i>S. clavuligerus</i> <i>S. clavuligerus</i> <i>S. cattleya</i>	β -lactams (Cephamecins, Thienamycin): Bactericidal agents that inhibit cell wall synthesis β -lactamase inhibitors (Clavulanic acid): Prevent bacterial degradation of β -lactams.	[73–82]

PKS: Polyketide synthase; NRPS: Non-ribosomal peptide synthase. * *S. erythreus* has been renamed as *Saccharopolyspora erythraea*; *S. mediterranei* has been renamed as *Amycolatopsis rifamycinica*; *S. orientalis* has been renamed as *Amycolatopsis orientalis*.

Antibiotic production in *Streptomyces* is tightly regulated and usually coupled to the developmental stage and nutrient availability. The key regulator layers include global regulators and cluster-situated regulators. Examples of global regulators include Bld genes, which control morphological differentiation [42]; AdpA, a pleiotropic transcription factor that regulates both developmental and secondary metabolism [83]; and the ppGpp-mediated stringent response, linking nutrient stress to secondary metabolite production [20,83]. As for cluster-situated regulators, most BGCs encode one or more pathway-specific regulators, often belonging to the LuxR, SARP or TetT families [84–86]. These regulators fine-tune the expression of individual clusters in response to environmental or cellular cues. The complexity of this regulatory architecture explains why many antibiotic gene clusters remain cryptic and why genetic or environmental manipulation can unlock new compounds [10,87]. Unlike most bacteria, *Streptomyces* exhibits a filamentous, multicellular lifestyle reminiscent of fungi. Its life cycle includes vegetative hyphal growth, aerial hyphae formation, and sporulation [88]. Antibiotic production is typically initiated during the transition from vegetative growth to aerial development [89,90]. Genomically, this coupling is enforced by shared regulatory circuits controlling both morphogenesis and secondary metabolism. This strategy likely evolved as a competitive response in the soil environments, where antibiotic production coincides with nutrient limitation and sporulation, helping eliminate competitors while spores disperse.

3. Aminoglycosides

Aminoglycosides are a class of polycationic natural products best known for inhibiting bacterial protein synthesis [91]. Aminoglycosides share a few architectural characteristics. First, the most clinically important aminoglycosides contain a central 2-deoxystreptamine ring [92]. This six-membered cyclitol ring carries multiple amino groups. Second, two or more amino-modified sugars are glycosidically linked to the central core. These sugars are also highly hydroxylated and often further modified [43]. Third, the highly polar, polycationic nature enables binding to negatively charged ribosomal RNA in the bacterial 30S subunit [44].

3.1. Streptomycin

Streptomycin was named after the genus *Streptomyces*. It was discovered in 1944 during a systematic screening of soil microorganisms for antibacterial compounds [45]. Although streptomycin was not the first antibiotic discovered from *Streptomyces* (actinomycin and streptothricin were discovered before streptomycin, but were too toxic for clinical use), it was the first to become clinically important [93]. Streptomycin was isolated from *S. griseus* and became the first effective antibiotic against *Mycobacterium tuberculosis*, marking a major breakthrough in tuberculosis treatment and earning its discoverer, Selman Waksman, the Nobel Prize in 1952 [21,94]. Its discovery established *Streptomyces* species as a prolific source of clinically important natural products. The structure of streptomycin is unique among the aminoglycosides, in that it lacks the classic 2-deoxystreptamine core [22].

Biosynthesis of streptomycin is carried out via a complex pathway encoded by the *str* gene cluster [95]. Streptomycin consists of three components: streptidine (a cyclitol), streptose (a sugar), and N-methyl-L-glucosamine (Figure 2A) [95]. Its biosynthesis begins with glucose-6-phosphate which is converted into the cyclitol streptidine through a series of oxidation, amination, and phosphorylation reactions [46]. Glycosyltransferases then attach activated sugar donors to form the disaccharide and ultimately the complete trisaccharide structure [96]. Tailoring enzymes perform methylation and other modifications to yield active streptomycin.

3.2. Neomycin

Neomycin was discovered in 1949 from *S. fradiae*, part of Selman Waksman's broader program on systematic screening of soil actinomycetes, which also yielded streptomycin [47]. Neomycin belongs to the 2-deoxystreptamine aminoglycoside family. Its biosynthesis is catalyzed by enzymes encoded in the *neo* gene cluster [97]. It begins with glucose-6-phosphate undergoing cyclization, amination, and dehydrogenation to produce 2-deoxystreptamine [98]. Glycosyltransferases attach amino sugar moieties derived from UDP-activated sugars. These include neosamine and ribose-like sugars. Additionally, amination, acetylation, and epimerization refine the final structure [99].




Figure 2. Highly diverse chemical structures of representative antibiotics produced by *Streptomyces* species. (A) Streptomycin, an aminoglycoside unique for lacking the 2-deoxystreptamine core found in neomycin and kanamycin. (B) Erythromycin A, a Type I polyketide characterized by a 14-membered macrolactone ring with attached sugars. (C) Tetracycline, a Type II polyketide defined by its four linearly fused rings. (D) Daptomycin, a cyclic lipopeptide synthesized by NRPS, features a 10-amino acid ring and a lipid tail that inserts into bacterial membranes. (E) Chloramphenicol, a simple phenylpropanoid containing a nitrobenzene group and a dichloroacetyl tail. (F) Clavulanic acid, a β -lactamase inhibitor containing the characteristic four-membered β -lactam ring.

3.3. Kanamycin

Kanamycin was discovered in 1957 in Japan from *S. kanamyceticus* [48]. It demonstrated strong activity against *M. tuberculosis* and became an important second-line treatment for tuberculosis [100]. Kanamycin exists as several closely related compounds: kanamycin A (clinically dominant), kanamycin B, and kanamycin C [101]. Like neomycin, kanamycin belongs to the 2-deoxystreptamine family and shares early biosynthetic steps. After forming the 2-deoxystreptamine, a glycosyltransferase attaches an N-acetylglucosamine-derived sugar to the 2-deoxystreptamine nucleus [102]. A second amino sugar is added, forming the trisaccharide scaffold characteristic of kanamycin. Oxidation, transamination, and deacetylation produce kanamycin A, B, or C [103].

3.4. Tobramycin

Tobramycin was discovered in the 1960s from *S. tenebrarius*. It is structurally closely related to kanamycin B [49]. Tobramycin biosynthesis shares extensive homology with the kanamycin pathway [104]. After forming the 2-deoxystreptamine, sequential attachment of amino sugars forms a kanamycin-like intermediate. A key distinguishing step is the removal of a hydroxyl group at the 3' position of one sugar moiety. The modification is catalyzed by specific dehydratase or reductase enzymes encoded in the *tob* gene cluster [105]. Transaminases and other modifying enzymes yield the final tobramycin structure [23].

4. Polyketides

Bacterial polyketides are a large and structurally diverse class of secondary metabolites derived from simple carboxylic acid building blocks, most commonly acetyl-CoA and malonyl-CoA [50]. Structurally, they are characterized by repeating carbon-carbon units formed through decarboxylative Claisen condensations [106]. This mode of assembly is conceptually similar to fatty acid biosynthesis, but polyketide synthesis allows far greater chemical variation [107,108]. As a result, polyketides can be linear, cyclic, aromatic, or highly oxygenated and decorated with sugars, methyl groups, or other functional moieties.

The biosynthesis of bacterial polyketides is catalyzed by PKSs, which are large, multi-enzyme systems. Three types of PKSs are recognized in bacteria: Type I, II, and III. Type I PKSs are large, modular, multifunctional proteins. Each module is responsible for one cycle of chain elongation and contains a defined set of catalytic domains [109]. The minimal domains include ketosynthase (which catalyzes carbon-carbon bond formation), acyltransferase (which selects and loads the extender unit), and acyl carrier protein (which tethers the growing

chain). Optional tailoring domains such as ketoreductase, dehydratase, and enoyl reductase modify the β -keto group after each condensation [50]. Type II PKSs consist of discrete, monofunctional enzymes that act iteratively rather than in a modular fashion. They typically produce aromatic polyketides [55]. A minimal Type II PKS includes a ketosynthase- α , a ketosynthase- β , and an acyl carrier protein, which together generate a poly- β -keto chain that later cyclizes and aromatizes [16,56]. Type III PKSs are simpler, homodimeric enzymes that do not use acyl carrier protein [110]. They directly use CoA-linked substrates and perform iterative condensations. Type III PKSs are not as common as Type I and II PKSs in bacteria. Once the polyketide backbone is assembled, chain release typically occurs via thioesterase-mediated hydrolysis or cyclization [111]. Extensive post-PKS tailoring follows, including oxygenation, reduction, glycosylation, methylation, and halogenation. These steps are crucial for biological activity and often determine the final pharmacological properties of the compound [112].

4.1. Erythromycin

Erythromycin was discovered in 1949 during the post-World War II golden age of antibiotic research, closely tied to systematic soil-screening programs aimed at identifying novel antimicrobial compounds produced by *Streptomyces* species [113]. A soil sample collected from the Philippines yielded a microorganism that produced a potent antibacterial compound distinct from penicillin and streptomycin, the dominant antibiotics of the era. The producing organism was initially named *S. erythreus*, reflecting the reddish pigmentation of its colonies [51]. At a time when penicillin resistance was becoming an increasing concern, erythromycin quickly gained attention because of its effectiveness against penicillin-resistant *Staphylococcus aureus* [114]. Moreover, it was also less allergenic than penicillin, making it a valuable alternative for patients with penicillin hypersensitivity [115]. Structurally, erythromycin is defined by a 14-membered macrolactone ring decorated with two deoxy sugars: desosamine and cladinose (Figure 2B) [116]. These features are critical for its antibacterial activity, which arises from binding to the bacterial 50S ribosomal subunit and inhibiting protein synthesis [52].

The biosynthesis of erythromycin is one of the best-studied examples of bacterial polyketide biosynthesis and provides key insights into modular enzyme systems. The core macrolactone, 6-deoxyerythronolide B, is assembled by a Type I modular PKS known as 6-deoxyerythronolide B synthase (DEBS), which consists of three large multifunctional proteins (DEBS1, DEBS2 and DEBS3), which together contain six sequential modules [117]. Each module catalyzes one round of chain elongation using methylmalonyl-CoA as the extender unit, starting from a propionyl-CoA primer [118]. The collinearity between PKS modules and the structure of 6-deoxyerythronolide B was a key piece of evidence supporting the modular paradigm of Type I PKSs [119]. Within each module, the ketosynthase, acyltransferase, and acyl carrier protein domains form the core catalytic machinery. After six cycles of elongation and processing, the thioesterase domain catalyzes macrolactonization, releasing the 14-membered ring. After forming 6-deoxyerythronolide B, the molecule undergoes extensive post-PKS tailoring. Hydroxylation at C-6 by a cytochrome P450 enzyme produces erythronolide B [120]. glycosyltransferases then attach the sugars desosamine and cladinose, which are themselves synthesized through dedicated deoxysugar biosynthetic pathways [24]. Additional methylation and modifications yield the final active antibiotic, erythromycin A. This natural antibiotic can be further chemically converted into additional semi-synthetic macrolides, such as clarithromycin and azithromycin, which have longer half-lives, different antibacterial spectra, etc. [121].

4.2. Tetracycline

Similar to erythromycin, tetracycline was discovered during a systematic screening program for new antibiotics. In 1948, chlortetracycline was first discovered from *S. aureofaciens* and was marketed as aureomycin [57]. Shortly thereafter, oxytetracycline was discovered in 1950 from *S. rimosus* [122], and tetracycline itself was identified in 1953 (Figure 2C) [25]. Its improved stability and broad antimicrobial spectrum make it particularly attractive for clinical use. The development of fermentation-based large-scale production methods allowed tetracyclines to become widely accessible. Overtime, semi-synthetic derivatives such as doxycycline and minocycline were developed to improve pharmacokinetic properties and overcome emerging resistance [25].

Tetracycline biosynthesis in *Streptomyces* species occurs via a type II PKS system that catalyzes the formation of the tetracycline carbon backbone [123]. The polyketide chain then undergoes controlled cyclization to form the characteristic four-ring structure of tetracycline. Following cyclization, the nascent tetracycline scaffold is extensively modified by tailoring enzymes, such as oxygenases, methyltransferases, aminotransferases, and hydroxylases [58]. These enzymes introduce functional groups critical for antibiotic activity. For example, aminotransferase-mediated introduction of the dimethylamino group at the C4 position is essential for binding to bacterial ribosomes [58]. The BGC also encodes self-resistance mechanisms such as efflux pumps and ribosomal protection protein, enabling the producing organism to avoid autotoxicity [124–126].

4.3. Rifampicin

Rifampicin is a semi-synthetic antibiotic renowned for its potent activity against *M. tuberculosis* [127]. Similar [107,108] to erythromycin and tetracycline, it was discovered in the late 1940s–1950s, during a period of intensive global screening for novel antibiotics from soil microorganisms [128]. In 1957, researchers isolated a new actinomycete from a soil sample collected in France [129]. The organism was named as *S. mediterranei*, which was subsequently reclassified and renamed as *Amycolatopsis rifamycinica* [13]. This microbe produced a group of structurally related compounds collectively termed rifampicins, among which rifamycin B showed promising antibacterial activity. Subsequent studies revealed that rifamycin B itself had limited oral bioavailability, prompting efforts to generate more clinically useful derivatives [130]. Through chemical modification, rifampicin was developed in the early 1960s by introducing a piperazine ring and other structural changes that enhanced stability, oral absorption, and antimicrobial potency [131]. Rifampicin was officially introduced into clinical practice in the late 1960s and rapidly became a cornerstone of tuberculosis therapy [26]. It has a unique mechanism of action, selective inhibition of bacterial DNA-dependent RNA polymerase, and is highly effective against slow-growing mycobacteria [53]. This has enabled the treatment duration of tuberculosis to be markedly reduced through various combination treatments using isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin. Rifampicin is also an important drug for the treatment of other mycobacterial infections, such as leprosy, caused by *M. leprae* (combination of rifampicin, dapsone, and clofazimine) [132] and *M. avium* complex infection (combination of clarithromycin/azithromycin, ethambutol, and rifampicin) [133].

The biosynthesis of rifampicin begins with the formation of the rifamycin core by a Type I modular PKS system encoded by the *rif* gene cluster in *A. rifamycinica* [54]. This gene cluster spans over 90 kb and contains genes responsible for polyketide assembly, tailoring reactions, regulation, and export [54]. The process is initiated by the unusual starter unit 3-amino-5-hydroxybenzoic acid (AHBA), which distinguishes rifamycins from many other polyketides [134]. AHBA is synthesized via a dedicated pathway involving intermediates from the shikimate and amino acid biosynthetic routes [135]. Once formed, AHBA is loaded onto the PKS machinery. The PKS chain is then elongated through successive condensations of acetate and propionate units, catalyzed by a series of PKS modules [136]. Each module introduces specific chemical modifications, such as ketoreduction, dehydration, and enoyl reduction, resulting in the formation of a linear polyketide intermediate. This intermediate undergoes macrocyclization to form the characteristic ansa macrolactam ring, a defining structural feature of rifamycins [137]. Following polyketide assembly. Extensive post-PKS tailoring reactions occur. These include oxidation, hydroxylation, methylation, and glycosylation steps, mediated by enzymes encoded with the *rif* cluster [138]. The primary natural product formed is rifamycin B, which can then be chemically converted into rifampicin through semi-synthetic processes.

5. Non-Ribosomal Peptides

Bacterial NRPs are a large class of biologically active secondary metabolites synthesized independently of the ribosome. Unlike ribosomal peptides, which are translated directly from mRNA, NRPs are assembled by massive, multi-enzyme complexes called NRPSs [59]. NRPs often have complex structures that include unusual amino acids, D-amino acids, fatty acids, and extensive modifications [60]. This structural diversity gives rise to a wide range of biological activities [61]. NRPS enzymes operate in a modular assembly-line fashion. Each module is responsible for incorporating one specific building block into the growing peptide chain [59]. A typical module contains an adenylation domain that selects and activates a specific amino acid, a thiolation domain that temporarily holds the activated amino acid via a phosphopantetheine arm, and a condensation domain that forms the peptide bond [62]. Additional domains may epimerize L-amino acids to D-forms, methylate residues, cyclize structures, oxidize, or reduce functional groups [17]. The final peptide is usually released by a thioesterase domain, often resulting in cyclization. Since NRPS systems are not constrained by the genetic code or ribosomal machinery, they can incorporate many unusual building blocks and generate structurally complex molecules [63].

5.1. Vancomycin and Teicoplanin

Vancomycin was discovered in 1953 from a soil sample collected in Borneo [139]. The producing bacterium was *S. orientalis*, subsequently renamed as *A. orientalis* [64]. It was introduced clinically in 1958. Although attention was only mild in the beginning with the availability of β -lactams, interest resurged in the 1980s due to the emergence of methicillin-resistant *Staphylococcus aureus* [140]. Teicoplanin was discovered in the late 1970s, from *Actinoplanes teichomyceticus*, isolated from a soil sample in Italy [141]. It belongs to the same class as vancomycin—the glycopeptide antibiotics—but differs structurally by having a lipophilic side chain and existing as a mixture of closely related compounds (teicoplanin A2 complex) [142]. It was introduced clinically in the

1980s [27]. Both vancomycin and teicoplanin act by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, preventing cell wall synthesis in Gram-positive bacteria [65]. Although they both have a similar spectrum of activity, teicoplanin has a longer half-life and lower nephrotoxicity than vancomycin [143].

Vancomycin and teicoplanin are nonribosomal glycopeptide antibiotics, synthesized by NRPSs. A defining feature of glycopeptides is their rigid, crosslinked three-dimensional structure. After assembly of the linear peptide by the corresponding NRPS, a series of cytochrome P450 monooxygenases catalyze oxidative phenolic coupling reactions [144]. These reactions form aryl-ether and biaryl crosslinks between aromatic side chains, generating the characteristic cup-shaped scaffold essential for D-Ala-D-Ala binding [145]. Further tailoring steps catalyzed by specific enzymes differentiate vancomycin from teicoplanin. In vancomycin, the sugar moiety vancosamine is added by glycosyltransferase and chlorine atoms are introduced by halogenases [146]; and for teicoplanin, an additional lipid side chain is attached, increasing membrane anchoring and prolonging half-life [147]. These tailoring enzymes are encoded within the BGCs, which also often include genes for self-resistance (e.g., altered cell wall precursors such as D-Ala-D-Lac) [18].

5.2. Daptomycin

Daptomycin is a cyclic lipopeptide antibiotic discovered during a natural products screening program in the late 1980s [66]. It was isolated from the soil actinomycete *S. roseosporus* [66]. However, early clinical development in the 1990s was halted due to concerns about skeletal muscle toxicity [148]. Interest in the compound was revived later after optimization of the dosing regimen, significantly reducing toxicity. Currently, daptomycin is particularly important for the treatment of methicillin-resistant *S. aureus* and vancomycin-resistant enterococci infections [149,150]. Structurally, daptomycin is a cyclic lipopeptide composed of a 13-amino-acid peptide core with a decanoyl fatty acid tail attached to the N-terminus (Figure 2D) [151]. The peptide contains several nonproteinogenic amino acids, including D-amino acids and unusual residues such as L-kynurenine and 3-methylglutamic acid [152]. A distinctive feature is its macrolactone ring, formed through an ester bond between the threonine residue and the terminal kynurenine residue [153]. This cyclic structure is essential for its biological activity. The lipid tail is also critical, enabling calcium-dependent insertion into bacterial membranes, which ultimately leads to membrane depolarization and rapid cell death [67].

The biosynthesis of daptomycin occurs via a NRPS pathway encoded by the *dpt* cluster in the *S. roseosporus* genome [28]. The daptomycin NRPS machinery consists of three large synthetase proteins (DptA, DptBC and DptD), which together contain 13 modules corresponding to the 13 amino acids of the peptide core [28]. Each module typically includes an adenylation domain, which selects and activates a specific amino acid as an aminoacyl-AMP; a thiolation domain, also known as a peptidyl carrier protein, which tethers the activated amino acid via a phosphopantetheine arm; and a condensation domain, which catalyzes peptide bond formation [154]. Some modules also contain epimerization domains that convert L-amino acids to their D-forms, accounting for the presence of D-residues in daptomycin [28]. The lipid tail is incorporated at the initiation stage by a specialized acyltransferase that attaches a fatty acid to the first amino acid before peptide elongation proceeds. After assembly of the linear lipopeptide chain, a thioesterase domain at the terminus of the NRPS catalyzes cyclization and release of the mature molecule, forming the characteristic macrolactone ring [155]. Additional tailoring enzymes encoded within the gene cluster are responsible for generating unusual amino acid precursors, such as kynurenine from tryptophan [156].

6. Chloramphenicol

Chloramphenicol was discovered in 1947 during a screening program for antimicrobial compounds from soil actinomycetes [157]. It was isolated from *S. venezuelae* [68]. Structurally, it is distinct from many other natural product antibiotics. It is a small molecule containing a nitrobenzene ring, a dichloroacetamide moiety, and a propanediol side chain with two stereocenters [158]. Unlike peptide-based antibiotics or complex polyketides, chloramphenicol has a relatively simple architecture (Figure 2E), which makes it the first antibiotic to be produced on a large scale by total chemical synthesis rather than solely by fermentation [159].

The biosynthesis of chloramphenicol in *S. venezuelae* is encoded by the *cml* gene cluster [69]. Chloramphenicol is derived primarily from chorismate, an intermediate of the shikimate pathway, which is responsible for aromatic amino acid biosynthesis [69]. Chorismate is converted into p-aminophenylalanine, a key precursor that provides the aromatic ring structure [19]. Once formed, the amino group on the aromatic ring of p-aminophenylalanine is oxidized to a nitro group through a multistep enzymatic process [70]. Concurrently, enzymes construct the dichloroacetyl side chain, which is derived from central metabolic intermediates and subsequently chlorinated. Halogenation is catalyzed by specific halogenases encoded within the gene cluster,

introducing two chlorine atoms that are essential for biological activity [71]. The final assembly step links the dichloroacetyl moiety to the propanediol side chain and aromatic core via amide bond formation. Stereospecific enzymes ensure the correct configuration of the two chiral centers in the propanediol unit, critical for ribosomal binding [72]. The completed molecule is exported from the producing organism. And resistance genes within the cluster encode chloramphenicol acetyltransferases that inactivate the antibiotic intracellularly, protecting the host bacterium [69].

7. β -Lactams

β -lactam antibiotics share a core four-membered cyclic amide ring known as the β -lactam ring [160]. This ring consists of three carbon atoms and one nitrogen atom. The β -lactam ring is essential for antibacterial activity, as it binds to penicillin-binding proteins and inhibits bacterial cell wall synthesis [73]. Although β -lactams as a group consist of the largest number of commercially available antibiotics, only a few of them are directly or indirectly originated from *Streptomyces* species, the most notable ones being cefoxitin, imipenem and clavulanic acid [74,75,161].

7.1. Cephameycins and Cefoxitin

Cephameycins were discovered in the early 1970s during efforts to identify naturally occurring β -lactam antibiotics with improved resistance to β -lactamases [161]. Cephameycins possess an unusual 7- α -methoxy group on the β -lactam nucleus, which confers enhanced stability against many β -lactamases compared to earlier cephalosporins [29]. Cefoxitin is a semi-synthetic derivative of cephameycin C, a compound isolated from *S. lactamdurans* [162,163].

Biosynthesis of cephameycin C begins with formation of the tripeptide precursor L- α -aminoadipate, L-cysteine and L-valine, assembled by a NRPS [76]. This linear tripeptide cyclizes to form isopenicillin N via isopenicillin N synthase. Unlike penicillin biosynthesis in fungi, the pathway in *Streptomyces* proceeds through ring expansion to form the cephem nucleus, and a defining step in cephameycin production is the introduction of the 7- α -methoxy group, catalyzed by specific oxygenase and methyltransferase encoded in the cephameycin gene cluster [77–79]. Cefoxitin is then produced by chemical modification of cephameycin C, particularly alteration of the 3-position side chain to improve antibacterial activity and stability [163].

7.2. Clavulanic Acid

Clavulanic acid was discovered in 1976 during a screening program for new β -lactam antibiotics [164]. It was isolated from *S. clavuligerus*, a soil-dwelling actinomycete [75]. Although clavulanic acid contains a β -lactam ring, it showed only weak intrinsic antibacterial activity. However, it was found to be a potent β -lactamase inhibitor [165]. It binds to β -lactamases and protects co-administered antibiotics [75]. Its clinical importance was established through combination with amoxicillin, marketed as Augmentin [166,167].

Unlike penicillins and cephalosporins, which are derived from amino acid precursors via peptide assembly, clavulanic acid biosynthesis originates from primary metabolic intermediates. The gene cluster encodes enzymes for precursor supply, β -lactam formation, tailoring reactions, regulation, and self-resistance [168–170]. The pathway begins with the condensation of glyceraldehyde-3-phosphate and L-arginine-derived units [171]. Then, an oxidative cyclization step forms the characteristic β -lactam ring, but notably without the fused thiazolidine or dihydrothiazine rings seen in penicillins and cephalosporins [172]. Lastly, several oxygenase-mediated steps modify the intermediate clavaminic acid to generate the final bicyclic clavulanic acid (Figure 2F) [169,173].

7.3. Thienamycin and Imipenem

Thienamycin, a naturally occurring carbapenem antibiotic, was discovered in the late 1970s from *S. cattleya* [74]. It has an exceptionally broad antibacterial spectrum and strong resistance to most β -lactamases [174]; however, thienamycin was chemically unstable in aqueous solution, limiting direct clinical use [175]. Imipenem was created as a more stable N-formimidoyl derivative of thienamycin through chemical modification [174]. It became the first clinically useful carbapenem antibiotic and was introduced in the 1980s [176]. Since it is hydrolyzed in the kidney by dehydropeptidase I, it is co-administered with cilastatin, an enzyme inhibitor that prevents renal degradation and prolongs its activity [177,178].

Biosynthesis of thienamycin is catalyzed by enzymes encoded in the *thn* cluster [179]. It begins with the assembly of a simple precursor derived from malonyl-CoA and amino acid building blocks [80]. β -lactam ring formation is catalyzed by carbapenem synthase [81]. Unlike penicillins, carbapenems lack sulfur in the fused ring

and instead contain a carbon-based unsaturated five-membered ring [179]. Then, oxygenases and other tailoring enzymes introduce double bonds and stereochemical features essential for activity, and the characteristic cysteaminy side chain is formed [82].

8. Concluding Remarks and Future Perspectives

Among all bacterial genera, *Streptomyces* has been the most prolific in producing clinically useful antibiotics. So far, most of the antibiotics from *Streptomyces* have been discovered through screening soil samples. From the 1940s to 1970s, researchers collected soil from diverse environments, isolated *Streptomyces* strains, cultured them, and screened their metabolites for activity against pathogenic bacteria [180–182]. In the last few decades, antibiotic resistance has exploded, and the discovery of new antibiotics has become a high priority [183–186]. With advances in technology, it is expected that newer approaches will be used to discover natural antibiotics from *Streptomyces*. For example, whole-genome sequencing through the expanding next-generation sequencing platforms and downstream bioinformatics analysis will be able to predict BGCs that encode secondary metabolites, such as novel polyketides, NRPs, and other antibiotic classes. Metagenomic sequencing of environmental DNA samples will also lead to the discovery of BGCs from *Streptomyces* that cannot be cultured. Artificial intelligence can help analyze large genomic datasets to identify and classify BGCs more accurately than rule-based bioinformatics alone [187]. It can also predict which gene clusters are most likely to produce bioactive compounds. This allows us to prioritize the most promising clusters rather than experimentally testing hundreds at random. As a whole, these advanced techniques and rigorous in silico analysis could lead to revealing the hidden BGCs in *Streptomyces*, enabling genome mining, activation of silent pathways, and discovery of entirely new antibiotics that traditional methods would miss [188–190].

Author Contributions

Conceived and designed the study: P.C.Y.W. Literature search: E.W.T.T., S.K.P.L. and P.C.Y.W. Writing—original draft: E.W.T.T., S.K.P.L. and P.C.Y.W. Writing—review and editing: E.W.T.T., S.K.P.L. and P.C.Y.W. All authors have read and agreed to the published version of the manuscript.

Funding

This work was partly supported by the Feature Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE-115-S-0023-A) in Taiwan.

Conflicts of Interest

The authors declare no conflict of interest.

Use of AI and AI-Assisted Technologies

No AI tools were utilized for this paper.

References

1. Conly, J.; Johnston, B. Where are all the new antibiotics? The new antibiotic paradox. *Can. J. Infect. Dis. Med. Microbiol.* **2005**, *16*, 159–160.
2. Hutchings, M.I.; Truman, A.W.; Wilkinson, B. Antibiotics: Past, present and future. *Curr. Opin. Microbiol.* **2019**, *51*, 72–80.
3. Hibbing, M.E.; Fuqua, C.; Parsek, M.R.; et al. Bacterial competition: Surviving and thriving in the microbial jungle. *Nat. Rev. Microbiol.* **2010**, *8*, 15–25.
4. Cornforth, D.M.; Foster, K.R. Competition sensing: The social side of bacterial stress responses. *Nat. Rev. Microbiol.* **2013**, *11*, 285–293.
5. Shepherdson, E.M.; Baglio, C.R.; Elliot, M.A. *Streptomyces* behavior and competition in the natural environment. *Curr. Opin. Microbiol.* **2023**, *71*, 102257.
6. Watve, M.G.; Tickoo, R.; Jog, M.M.; et al. How many antibiotics are produced by the genus *Streptomyces*? *Arch. Microbiol.* **2001**, *176*, 386–390.
7. Bentley, S.D.; Chater, K.F.; Cerdeno-Tarraga, A.M.; et al. Complete genome sequence of the model actinomycete *Streptomyces coelicolor* A3(2). *Nature* **2002**, *417*, 141–147.
8. Ikeda, H.; Ishikawa, J.; Hanamoto, A.; et al. Complete genome sequence and comparative analysis of the industrial microorganism *Streptomyces avermitilis*. *Nat. Biotechnol.* **2003**, *21*, 526–531.

9. Wang, X.J.; Yan, Y.J.; Zhang, B.; et al. Genome sequence of the milbemycin-producing bacterium *Streptomyces bingchenggensis*. *J. Bacteriol.* **2010**, *192*, 4526–4527.
10. Augustijn, H.E.; van Nassauw, D.; Cernat, S.; et al. Regulatory genes as beacons for discovery and prioritization of biosynthetic gene clusters in *Streptomyces*. *Biochemistry* **2025**, *64*, 2877–2885.
11. Sensi, P.; Margalith, P.; Timbal, M.T. Rifomycin, a new antibiotic; preliminary report. *Farm. Sci.* **1959**, *14*, 146–147.
12. Sensi, P.; Greco, A.M.; Ballotta, R. Rifomycin. I. Isolation and properties of rifomycin B and rifomycin complex. *Antibiot. Annu.* **1959**, *7*, 262–270.
13. Bala, S.; Khanna, R.; Dadhwal, M.; et al. Reclassification of *Amycolatopsis mediterranei* DSM 46095 as *Amycolatopsis rifamycinica* sp. nov. *Int. J. Syst. Evol. Microbiol.* **2004**, *54*, 1145–1149.
14. Levine, D.P. Vancomycin: A history. *Clin. Infect. Dis.* **2006**, *42*, S5–12.
15. Jeong, H.; Sim, Y.M.; Kim, H.J.; et al. Genome sequence of the vancomycin-producing *Amycolatopsis orientalis* subsp. *orientalis* Strain KCTC 9412T. *Genome Announc.* **2013**, *1*, e00408–13.
16. Zhang, Z.; Pan, H.X.; Tang, G.L. New insights into bacterial type II polyketide biosynthesis. *F1000Research* **2017**, *6*, 172.
17. Walsh, C.T.; Chen, H.; Keating, T.A.; et al. Tailoring enzymes that modify nonribosomal peptides during and after chain elongation on NRPS assembly lines. *Curr. Opin. Chem. Biol.* **2001**, *5*, 525–534.
18. Marshall, C.G.; Broadhead, G.; Leskiw, B.K.; et al. D-Ala-D-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 6480–6483.
19. Jones, A.; Vining, L.C. Biosynthesis of chloramphenicol in *Streptomyces* sp. 3022a. Identification of p-amino-L-phenylalanine as a product from the action of arylamine synthetase on chorismic acid. *Can. J. Microbiol.* **1976**, *22*, 237–244.
20. Hesketh, A.; Sun, J.; Bibb, M. Induction of ppGpp synthesis in *Streptomyces coelicolor* A3(2) grown under conditions of nutritional sufficiency elicits actII-ORF4 transcription and actinorhodin biosynthesis. *Mol. Microbiol.* **2001**, *39*, 136–144.
21. Kingston, W. Streptomycin, Schatz v. Waksman, and the balance of credit for discovery. *J. Hist. Med. Allied Sci.* **2004**, *59*, 441–462.
22. Mingot-Leclercq, M.P.; Glupczynski, Y.; Tulkens, P.M. Aminoglycosides: Activity and resistance. *Antimicrob. Agents Chemother.* **1999**, *43*, 727–737.
23. Hirayama, T.; Tamegai, H.; Kudo, F.; et al. Biosynthesis of 2-deoxystreptamine-containing antibiotics in *Streptoalloteichus hindustanus* JCM 3268: Characterization of 2-deoxy-scylo-inosose synthase. *J. Antibiot.* **2006**, *59*, 358–361.
24. Summers, R.G.; Donadio, S.; Staver, M.J.; et al. Sequencing and mutagenesis of genes from the erythromycin biosynthetic gene cluster of *Saccharopolyspora erythraea* that are involved in L-mycarose and D-desosamine production. *Microbiology* **1997**, *143*, 3251–3262.
25. Chopra, I.; Roberts, M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. *Microbiol. Mol. Biol. Rev.* **2001**, *65*, 232–260.
26. Grobbelaar, M.; Louw, G.E.; Sampson, S.L.; et al. Evolution of rifampicin treatment for tuberculosis. *Infect. Genet. Evol.* **2019**, *74*, 103937.
27. Lepout, C.; Perronne, C.; Massip, P.; et al. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. *Antimicrob. Agents Chemother.* **1989**, *33*, 871–876.
28. Miao, V.; Coeffet-LeGal, M.F.; Brian, P.; et al. Daptomycin biosynthesis in *Streptomyces roseosporus*: Cloning and analysis of the gene cluster and revision of peptide stereochemistry. *Microbiology* **2005**, *151*, 1507–1523.
29. Nagarajan, R.; Boeck, L.D.; Gorman, M.; et al. Beta-lactam antibiotics from *Streptomyces*. *J. Am. Chem. Soc.* **1971**, *93*, 2308–2310.
30. Blazic, M.; Starcevic, A.; Lisfi, M.; et al. Annotation of the modular polyketide synthase and nonribosomal peptide synthetase gene clusters in the genome of *Streptomyces tsukubaensis* NRRL18488. *Appl. Environ. Microbiol.* **2012**, *78*, 8183–8190.
31. Ayuso-Sacido, A.; Genilloud, O. New PCR primers for the screening of NRPS and PKS-I systems in actinomycetes: Detection and distribution of these biosynthetic gene sequences in major taxonomic groups. *Microb. Ecol.* **2005**, *49*, 10–24.
32. Lin, Y.S.; Kieser, H.M.; Hopwood, D.A.; Chen, C.W. The chromosomal DNA of *Streptomyces lividans* 66 is linear. *Mol. Microbiol.* **1993**, *10*, 923–933.
33. Medema, M.H.; Trefzer, A.; Kovalchuk, A.; et al. The sequence of a 1.8-mb bacterial linear plasmid reveals a rich evolutionary reservoir of secondary metabolic pathways. *Genome Biol. Evol.* **2010**, *2*, 212–224.
34. Kinashi, H.; Shimaji, M.; Sakai, A. Giant linear plasmids in *Streptomyces* which code for antibiotic biosynthesis genes. *Nature* **1987**, *328*, 454–456.
35. Choulet, F.; Aigle, B.; Gallois, A.; et al. Evolution of the terminal regions of the *Streptomyces* linear chromosome. *Mol. Biol. Evol.* **2006**, *23*, 2361–2369.

36. Conte, J.E., Jr. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. *J. Infect. Dis.* **1991**, *163*, 169–175.
37. Fischbach, M.A.; Walsh, C.T. Assembly-line enzymology for polyketide and nonribosomal Peptide antibiotics: Logic, machinery, and mechanisms. *Chem. Rev.* **2006**, *106*, 3468–3496.
38. Scherlach, K.; Hertweck, C. Triggering cryptic natural product biosynthesis in microorganisms. *Org. Biomol. Chem.* **2009**, *7*, 1753–1760.
39. Rutledge, P.J.; Challis, G.L. Discovery of microbial natural products by activation of silent biosynthetic gene clusters. *Nat. Rev. Microbiol.* **2015**, *13*, 509–523.
40. Thaker, M.N.; Wang, W.; Spanogiannopoulos, P.; et al. Identifying producers of antibacterial compounds by screening for antibiotic resistance. *Nat. Biotechnol.* **2013**, *31*, 922–927.
41. Woo, P.C.; Lau, S.K.; Huang, Y.; et al. Genomic evidence for antibiotic resistance genes of actinomycetes as origins of antibiotic resistance genes in pathogenic bacteria simply because actinomycetes are more ancestral than pathogenic bacteria. *Med. Hypotheses* **2006**, *67*, 1297–1304.
42. Linares, J.F.; Gustafsson, I.; Baquero, F.; et al. Antibiotics as intermicrobial signaling agents instead of weapons. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 19484–19489.
43. Corzana, F.; Cuesta, I.; Freire, F.; et al. The pattern of distribution of amino groups modulates the structure and dynamics of natural aminoglycosides: Implications for RNA recognition. *J. Am. Chem. Soc.* **2007**, *129*, 2849–2865.
44. Carter, A.P.; Clemons, W.M.; Brodersen, D.E.; et al. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. *Nature* **2000**, *407*, 340–348.
45. Schatz, A.; Bugle, E.; Waksman, S.A. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. *Proc. Soc. Exp. Biol. Med.* **1944**, *55*, 66–69.
46. Flatt, P.M.; Mahmud, T. Biosynthesis of aminocyclitol-aminoglycoside antibiotics and related compounds. *Nat. Prod. Rep.* **2007**, *24*, 358–392.
47. Waksman, S.A.; Lechevalier, H.A. Neomycin, a new antibiotic active against streptomycin-resistant bacteria, including tuberculosis organisms. *Science* **1949**, *109*, 305–307.
48. Umezawa, H.; Ueda, M.; Maeda, K.; et al. Production and isolation of a new antibiotic: *Kanamycin*. *J. Antibiot.* **1957**, *10*, 181–188.
49. Stark, W.M.; Hoehn, M.M.; Knox, N.G. Nebramycin, a new broad-spectrum antibiotic complex. I. Detection and biosynthesis. *Antimicrob. Agents Chemother.* **1967**, *7*, 314–323.
50. Jenke-Kodama, H.; Dittmann, E. Evolution of metabolic diversity: Insights from microbial polyketide synthases. *Phytochemistry* **2009**, *70*, 1858–1866.
51. Mcguire, J.M.; Bunch, R.L.; Anderson, R.C.; et al. Ilotycin, a new antibiotic. *Antibiot. Chemother.* **1952**, *2*, 281–283.
52. Schlunzen, F.; Zarivach, R.; Harms, J.; et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. *Nature* **2001**, *413*, 814–821.
53. Campbell, E.A.; Korzheva, N.; Mustaev, A.; et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. *Cell* **2001**, *104*, 901–912.
54. August, P.R.; Tang, L.; Yoon, Y.J.; et al. Biosynthesis of the ansamycin antibiotic rifamycin: Deductions from the molecular analysis of the rif biosynthetic gene cluster of *Amycolatopsis mediterranei* S699. *Chem. Biol.* **1998**, *5*, 69–79.
55. Hertweck, C.; Luzhetskyy, A.; Rebets, Y.; et al. Type II polyketide synthases: Gaining a deeper insight into enzymatic teamwork. *Nat. Prod. Rep.* **2007**, *24*, 162–190.
56. McBride, C.M.; Miller, E.L.; Charkoudian, L.K. An updated catalogue of diverse type II polyketide synthase biosynthetic gene clusters captured from large-scale nucleotide databases. *Microb. Genom.* **2023**, *9*, mgen000965.
57. Duggar, B.M. Aureomycin; a product of the continuing search for new antibiotics. *Ann. N. Y. Acad. Sci.* **1948**, *51*, 177–181.
58. Zhang, W.; Ames, B.D.; Tsai, S.C.; et al. Engineered biosynthesis of a novel amidated polyketide, using the malonamyl-specific initiation module from the oxytetracycline polyketide synthase. *Appl. Environ. Microbiol.* **2006**, *72*, 2573–2580.
59. Finking, R.; Marahiel, M.A. Biosynthesis of nonribosomal peptides. *Annu. Rev. Microbiol.* **2004**, *58*, 453–488.
60. Marahiel, M.A. Working outside the protein-synthesis rules: Insights into non-ribosomal peptide synthesis. *J. Pept. Sci.* **2009**, *15*, 799–807.
61. Caboche, S.; Leclere, V.; Pupin, M.; et al. Diversity of monomers in nonribosomal peptides: Towards the prediction of origin and biological activity. *J. Bacteriol.* **2010**, *192*, 5143–5150.
62. Schwarzer, D.; Finking, R.; Marahiel, M.A. Nonribosomal peptides: From genes to products. *Nat. Prod. Rep.* **2003**, *20*, 275–287.
63. Walsh, C.T. Polyketide and nonribosomal peptide antibiotics: Modularity and versatility. *Science* **2004**, *303*, 1805–1810.
64. Brigham, R.B.; Pittenger, R.C. *Streptomyces orientalis*, n. sp., the source of vancomycin. *Antibiot. Chemother.* **1956**, *6*, 642–647.

65. Reynolds, P.E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. *Eur. J. Clin. Microbiol. Infect. Dis.* **1989**, *8*, 943–950.
66. Tally, F.P.; DeBruin, M.F. Development of daptomycin for gram-positive infections. *J. Antimicrob. Chemother.* **2000**, *46*, 523–526.
67. Silverman, J.A.; Perlmutter, N.G.; Shapiro, H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **2003**, *47*, 2538–2544.
68. Doull, J.; Ahmed, Z.; Stuttard, C.; et al. Isolation and characterization of *Streptomyces venezuelae* mutants blocked in chloramphenicol biosynthesis. *J. Gen. Microbiol.* **1985**, *131*, 97–104.
69. He, J.; Magarvey, N.; Pirace, M.; et al. The gene cluster for chloramphenicol biosynthesis in *Streptomyces venezuelae* ISP5230 includes novel shikimate pathway homologues and a monomodular non-ribosomal peptide synthetase gene. *Microbiology* **2001**, *147*, 2817–2829.
70. Fernandez-Martinez, L.T.; Borsetto, C.; Gomez-Escribano, J.P.; et al. New insights into chloramphenicol biosynthesis in *Streptomyces venezuelae* ATCC 10712. *Antimicrob. Agents Chemother.* **2014**, *58*, 7441–7450.
71. Podzelinska, K.; Latimer, R.; Bhattacharya, A.; et al. Chloramphenicol biosynthesis: The structure of CmlS, a flavin-dependent halogenase showing a covalent flavin-aspartate bond. *J. Mol. Biol.* **2010**, *397*, 316–331.
72. Hahn, F.E.; Wissemann, C.L., Jr.; Hopps, H.E. Mode of action of chloramphenicol, II. Inhibition of bacterial D-polypeptide formation by an L-stereoisomer of chloramphenicol. *J. Bacteriol.* **1954**, *67*, 674–679.
73. Tipper, D.J.; Strominger, J.L. Mechanism of action of penicillins: A proposal based on their structural similarity to acyl-D-alanyl-D-alanine. *Proc. Natl. Acad. Sci. USA* **1965**, *54*, 1133–1141.
74. Kahan, J.S.; Kahan, F.M.; Goegelman, R.; et al. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. *J. Antibiot.* **1979**, *32*, 1–12.
75. Reading, C.; Cole, M. Clavulanic acid: A beta-lactamase-inhibiting beta-lactam from *Streptomyces clavuligerus*. *Antimicrob. Agents Chemother.* **1977**, *11*, 852–857.
76. Tahlan, K.; Moore, M.A.; Jensen, S.E. Delta-(L-alpha-aminoadipyl)-L-cysteiny-D-valine synthetase (ACVS): Discovery and perspectives. *J. Ind. Microbiol. Biotechnol.* **2017**, *44*, 517–524.
77. Luengo, J.M.; Lopez-Nieto, M.J.; Salto, F. Cyclization of phenylacetyl-L-cysteiny-D-valine to benzylpenicillin using cell-free extracts of *Streptomyces clavuligerus*. *J. Antibiot.* **1986**, *39*, 1144–1147.
78. Dotzlaw, J.E.; Yeh, W.K. Copurification and characterization of deacetoxycephalosporin C synthetase/hydroxylase from *Cephalosporium acremonium*. *J. Bacteriol.* **1987**, *169*, 1611–1618.
79. Coque, J.J.; Perez-Llarena, F.J.; Enguita, F.J.; et al. Characterization of the cmcH genes of *Nocardia lactamdurans* and *Streptomyces clavuligerus* encoding a functional 3'-hydroxymethylcephem O-carbamoyltransferase for cephamycin biosynthesis. *Gene* **1995**, *162*, 21–27.
80. Williamson, J.M.; Inamine, E.; Wilson, K.E.; et al. Biosynthesis of the beta-lactam antibiotic, thienamycin, by *Streptomyces cattleya*. *J. Biol. Chem.* **1985**, *260*, 4637–4647.
81. Stapon, A.; Li, R.; Townsend, C.A. Synthesis of (3S,5R)-carbapenam-3-carboxylic acid and its role in carbapenem biosynthesis and the stereoinversion problem. *J. Am. Chem. Soc.* **2003**, *125*, 15746–15747.
82. Bodner, M.J.; Phelan, R.M.; Freeman, M.F.; et al. Non-heme iron oxygenases generate natural structural diversity in carbapenem antibiotics. *J. Am. Chem. Soc.* **2010**, *132*, 12–13.
83. Song, Y.; Zhang, X.; Zhang, Z.; et al. Physiology and transcriptional analysis of ppGpp-related regulatory effects in *Streptomyces diastatochromogenes* 1628. *Microbiol. Spectr.* **2023**, *11*, e01200–22.
84. Wietzorrek, A.; Bibb, M. A novel family of proteins that regulates antibiotic production in streptomycetes appears to contain an OmpR-like DNA-binding fold. *Mol. Microbiol.* **1997**, *25*, 1181.
85. Yan, Y.S.; Yang, Y.Q.; Zhou, L.S.; et al. MilR3, a unique SARP family pleiotropic regulator in *Streptomyces bingchenggensis*. *Arch. Microbiol.* **2022**, *204*, 631.
86. Rodriguez-Garcia, A.; Combes, P.; Perez-Redondo, R.; et al. Natural and synthetic tetracycline-inducible promoters for use in the antibiotic-producing bacteria *Streptomyces*. *Nucleic Acids Res.* **2005**, *33*, e87.
87. Zerikly, M.; Challis, G.L. Strategies for the discovery of new natural products by genome mining. *ChemBioChem* **2009**, *10*, 625–633.
88. Flardh, K.; Buttner, M.J. *Streptomyces morphogenetics*: Dissecting differentiation in a filamentous bacterium. *Nat. Rev. Microbiol.* **2009**, *7*, 36–49.
89. Huang, J.; Lih, C.J.; Pan, K.H.; et al. Global analysis of growth phase responsive gene expression and regulation of antibiotic biosynthetic pathways in *Streptomyces coelicolor* using DNA microarrays. *Genes Dev.* **2001**, *15*, 3183–3192.
90. Manteca, A.; Alvarez, R.; Salazar, N.; et al. Mycelium differentiation and antibiotic production in submerged cultures of *Streptomyces coelicolor*. *Appl. Environ. Microbiol.* **2008**, *74*, 3877–3886.
91. Zierhut, G.; Piepersberg, W.; Bock, A. Comparative analysis of the effect of aminoglycosides on bacterial protein synthesis *in vitro*. *Eur. J. Biochem.* **1979**, *98*, 577–583.

92. Busscher, G.F.; Rutjes, F.P.; van Delft, F.L. 2-Deoxystreptamine: Central scaffold of aminoglycoside antibiotics. *Chem. Rev.* **2005**, *105*, 775–791.
93. Hedley-Whyte, J.; Milamed, D.R. Tuberculous scrofula: Belfast experience. *Ulster Med. J.* **2011**, *80*, 97–103.
94. Schatz, A.; Waksman, S.A. Effect of streptomycin and other antibiotic substances upon *Mycobacterium tuberculosis* and related organisms. *Proc. Soc. Exp. Biol. Med.* **1944**, *57*, 244–248.
95. Distler, J.; Mansouri, K.; Mayer, G.; et al. Streptomycin biosynthesis and its regulation in *Streptomyces*. *Gene* **1992**, *115*, 105–111.
96. Retzlaff, L.; Distler, J. The regulator of streptomycin gene expression, StrR, of *Streptomyces griseus* is a DNA binding activator protein with multiple recognition sites. *Mol. Microbiol.* **1995**, *18*, 151–162.
97. Huang, F.; Haydock, S.F.; Mironenko, T.; et al. The neomycin biosynthetic gene cluster of *Streptomyces fradiae* NCIMB 8233: Characterisation of an aminotransferase involved in the formation of 2-deoxystreptamine. *Org. Biomol. Chem.* **2005**, *3*, 1410–1418.
98. Llewellyn, N.M.; Spencer, J.B. Biosynthesis of 2-deoxystreptamine-containing aminoglycoside antibiotics. *Nat. Prod. Rep.* **2006**, *23*, 864–874.
99. Fan, Q.; Huang, F.; Leadlay, P.F.; et al. The neomycin biosynthetic gene cluster of *Streptomyces fradiae* NCIMB 8233: Genetic and biochemical evidence for the roles of two glycosyltransferases and a deacetylase. *Org. Biomol. Chem.* **2008**, *6*, 3306–3314.
100. Caminero, J.A.; Sotgiu, G.; Zumla, A.; et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. *Lancet Infect. Dis.* **2010**, *10*, 621–629.
101. Puius, Y.A.; Stievater, T.H.; Srikrishnan, T. Crystal structure, conformation, and absolute configuration of kanamycin A. *Carbohydr. Res.* **2006**, *341*, 2871–2875.
102. Yanai, K.; Murakami, T. The kanamycin biosynthetic gene cluster from *Streptomyces kanamyceticus*. *J. Antibiot.* **2004**, *57*, 351–354.
103. Park, J.W.; Park, S.R.; Nepal, K.K.; et al. Discovery of parallel pathways of kanamycin biosynthesis allows antibiotic manipulation. *Nat. Chem. Biol.* **2011**, *7*, 843–852.
104. Koch, K.F.; Rhoades, J.A. Structure of nebramycin factor 6, a new aminoglycosidic antibiotic. *Antimicrob. Agents Chemother.* **1970**, *10*, 309–313.
105. Kharel, M.K.; Basnet, D.B.; Lee, H.C.; et al. Isolation and characterization of the tobramycin biosynthetic gene cluster from *Streptomyces tenebrarius*. *FEMS Microbiol. Lett.* **2004**, *230*, 185–190.
106. Staunton, J.; Weissman, K.J. Polyketide biosynthesis: A millennium review. *Nat. Prod. Rep.* **2001**, *18*, 380–416.
107. Hopwood, D.A.; Sherman, D.H. Molecular genetics of polyketides and its comparison to fatty acid biosynthesis. *Annu. Rev. Genet.* **1990**, *24*, 37–66.
108. Donadio, S.; Staver, M.J.; McAlpine, J.B.; et al. Modular organization of genes required for complex polyketide biosynthesis. *Science* **1991**, *252*, 675–679.
109. Hutchinson, C.R. Microbial polyketide synthases: More and more prolific. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 3336–3338.
110. Yu, D.; Xu, F.; Zeng, J.; et al. Type III polyketide synthases in natural product biosynthesis. *IUBMB Life* **2012**, *64*, 285–295.
111. Katsuyama, Y.; Ohnishi, Y. Type III polyketide synthases in microorganisms. *Methods Enzymol.* **2012**, *515*, 359–377.
112. Dhakal, D.; Sohng, J.K.; Pandey, R.P. Engineering actinomycetes for biosynthesis of macrolactone polyketides. *Microb. Cell Fact.* **2019**, *18*, 137.
113. Haight, T.H.; Finland, M. Laboratory and clinical studies on erythromycin. *N. Engl. J. Med.* **1952**, *247*, 227–232.
114. Haight, T.H.; Finland, M. The antibacterial action of erythromycin. *Proc. Soc. Exp. Biol. Med.* **1952**, *81*, 175–183.
115. Shoemaker, E.H.; Yow, E.M. Erythromycin and related antibiotics: Applied pharmacology. *Pediatr. Clin. North. Am.* **1956**, *3*, 305–315.
116. Vester, B.; Douthwaite, S. Macrolide resistance conferred by base substitutions in 23S rRNA. *Antimicrob. Agents Chemother.* **2001**, *45*, 1–12.
117. McDaniel, R.; Thamchaipenet, A.; Gustafsson, C.; et al. Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 1846–1851.
118. Caffrey, P.; Bevirt, D.J.; Staunton, J.; et al. Identification of DEBS 1, DEBS 2 and DEBS 3, the multienzyme polypeptides of the erythromycin-producing polyketide synthase from *Saccharopolyspora erythraea*. *FEBS Lett.* **1992**, *304*, 225–228.
119. Katz, L. The DEBS paradigm for type I modular polyketide synthases and beyond. *Methods Enzymol.* **2009**, *459*, 113–142.
120. Weber, J.M.; Leung, J.O.; Swanson, S.J.; et al. An erythromycin derivative produced by targeted gene disruption in *Saccharopolyspora erythraea*. *Science* **1991**, *252*, 114–117.
121. Zuckerman, J.M. Macrolides and ketolides: Azithromycin, clarithromycin, telithromycin. *Infect. Dis. Clin. North. Am.* **2004**, *18*, 621–649.
122. Finlay, A.C.; Hobby, G.L.; et al. Terramycin, a new antibiotic. *Science* **1950**, *111*, 85.
123. Pickens, L.B.; Tang, Y. Decoding and engineering tetracycline biosynthesis. *Metab. Eng.* **2009**, *11*, 69–75.

124. McMurry, L.M.; Park, B.H.; Burdett, V.; et al. Energy-dependent efflux mediated by class L (tetL) tetracycline resistance determinant from streptococci. *Antimicrob. Agents Chemother.* **1987**, *31*, 1648–1650.
125. Testa, R.T.; Petersen, P.J.; Jacobus, N.V.; et al. *In vitro* and *in vivo* antibacterial activities of the glycolcycloclines, a new class of semisynthetic tetracyclines. *Antimicrob. Agents Chemother.* **1993**, *37*, 2270–2277.
126. Brodersen, D.E.; Clemons, W.M., Jr.; Carter, A.P.; et al. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. *Cell* **2000**, *103*, 1143–1154.
127. Nigam, A.; Almabruk, K.H.; Saxena, A.; et al. Modification of rifamycin polyketide backbone leads to improved drug activity against rifampicin-resistant *Mycobacterium tuberculosis*. *J. Biol. Chem.* **2014**, *289*, 21142–21152.
128. Lewis, K. Platforms for antibiotic discovery. *Nat. Rev. Drug Discov.* **2013**, *12*, 371–387.
129. Sensi, P. History of the development of rifampin. *Rev. Infect. Dis.* **1983**, *5*, S402–S406.
130. Cohn, H.D. Clinical studies with a new rifamycin derivative. *J. Clin. Pharmacol. J. New Drugs* **1969**, *9*, 118–125.
131. Maggi, N.; Pasqualucci, C.R.; Ballotta, R.; et al. Rifampicin: A new orally active rifamycin. *Chemotherapy* **1966**, *11*, 285–292.
132. Britton, W.J.; Lockwood, D.N. Leprosy. *Lancet* **2004**, *363*, 1209–1219.
133. Griffith, D.E.; Brown-Elliott, B.A.; Wallace, R.J., Jr. Thrice-weekly clarithromycin-containing regimen for treatment of *Mycobacterium kansasii* lung disease: Results of a preliminary study. *Clin. Infect. Dis.* **2003**, *37*, 1178–1182.
134. Floss, H.G.; Yu, T.W. Rifamycin-mode of action, resistance, and biosynthesis. *Chem. Rev.* **2005**, *105*, 621–632.
135. Floss, H.G. Natural products derived from unusual variants of the shikimate pathway. *Nat. Prod. Rep.* **1997**, *14*, 433–452.
136. Kim, C.-G.; Kirschning, A.; Bergon, P.; et al. Biosynthesis of 3-amino-5-hydroxybenzoic acid, the precursor of mC7N units in ansamycin antibiotics. *J. Am. Chem. Soc.* **1996**, *118*, 7486–7491.
137. Kim, C.G.; Yu, T.W.; Fryhle, C.B.; et al. 3-amino-5-hydroxybenzoic acid synthase, the terminal enzyme in the formation of the precursor of mC7N units in rifamycin and related antibiotics. *J. Biol. Chem.* **1998**, *273*, 6030–6040.
138. Yu, T.W.; Muller, R.; Muller, M.; et al. Mutational analysis and reconstituted expression of the biosynthetic genes involved in the formation of 3-amino-5-hydroxybenzoic acid, the starter unit of rifamycin biosynthesis in *Amycolatopsis mediterranei* S699. *J. Biol. Chem.* **2001**, *276*, 12546–12555.
139. Griffith, R.S. Vancomycin use--an historical review. *J. Antimicrob. Chemother.* **1984**, *14*, 1–5.
140. de Lencastre, H.; Oliveira, D.; Tomasz, A. Antibiotic resistant *Staphylococcus aureus*: A paradigm of adaptive power. *Curr. Opin. Microbiol.* **2007**, *10*, 428–435.
141. Parenti, F.; Beretta, G.; Berti, M.; et al. Teichomycins, new antibiotics from *Actinoplanes teichomyceticus* Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties. *J. Antibiot.* **1978**, *31*, 276–283.
142. Barna, J.C.; Williams, D.H. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. *Annu. Rev. Microbiol.* **1984**, *38*, 339–357.
143. Svetitsky, S.; Leibovici, L.; Paul, M. Comparative efficacy and safety of vancomycin versus teicoplanin: Systematic review and meta-analysis. *Antimicrob. Agents Chemother.* **2009**, *53*, 4069–4079.
144. Hubbard, B.K.; Walsh, C.T. Vancomycin assembly: nature's way. *Angew. Chem. Int. Ed. Engl.* **2003**, *42*, 730–765.
145. Kahne, D.; Leimkuhler, C.; Lu, W.; et al. Glycopeptide and lipoglycopeptide antibiotics. *Chem. Rev.* **2005**, *105*, 425–448.
146. Pelzer, S.; Sussmuth, R.; Heckmann, D.; et al. Identification and analysis of the balhimycin biosynthetic gene cluster and its use for manipulating glycopeptide biosynthesis in *Amycolatopsis mediterranei* DSM5908. *Antimicrob. Agents Chemother.* **1999**, *43*, 1565–1573.
147. Sosio, M.; Kloosterman, H.; Bianchi, A.; et al. Organization of the teicoplanin gene cluster in *Actinoplanes teichomyceticus*. *Microbiology* **2004**, *150*, 95–102.
148. Phillips, I.; Edwards, J.R. Introduction: The modern gladiatorial arena: Gram-positive pathogens versus new therapies. *Clin. Microbiol. Infect.* **2005**, *11*, I.
149. Steenbergen, J.N.; Alder, J.; Thorne, G.M.; et al. Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections. *J. Antimicrob. Chemother.* **2005**, *55*, 283–288.
150. Buttress, J.A.; Schafer, A.B.; Koh, A.; et al. The last resort antibiotic daptomycin exhibits two independent antibacterial mechanisms of action. *Nat. Commun.* **2025**, *16*, 10320.
151. Miller, W.R.; Bayer, A.S.; Arias, C.A. Mechanism of action and resistance to daptomycin in *Staphylococcus aureus* and enterococci. *Cold Spring Harb. Perspect. Med.* **2016**, *6*, a026997.
152. Bionda, N.; Pitteloud, J.P.; Cudic, P. Cyclic lipodepsipeptides: A new class of antibacterial agents in the battle against resistant bacteria. *Future Med. Chem.* **2013**, *5*, 1311–1330.
153. Zakharova, A.A.; Efimova, S.S.; Ostroumova, O.S. State of the art of cyclic lipopeptide-membrane interactions: Pore formation and bilayer permeability. *Pharmaceutics* **2025**, *17*, 1142.
154. Baltz, R.H.; Miao, V.; Wrigley, S.K. Natural products to drugs: Daptomycin and related lipopeptide antibiotics. *Nat. Prod. Rep.* **2005**, *22*, 717–741.

155. Kopp, F.; Grunewald, J.; Mahlert, C.; et al. Chemoenzymatic design of acidic lipopeptide hybrids: New insights into the structure-activity relationship of daptomycin and A54145. *Biochemistry* **2006**, *45*, 10474–10481.
156. Nguyen, K.T.; Ritz, D.; Gu, J.Q.; et al. Combinatorial biosynthesis of novel antibiotics related to daptomycin. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 17462–17467.
157. Ehrlich, J.; Bartz, Q.R.; Smith, R.M.; et al. Chloramycetin, a new antibiotic from a soil actinomycete. *Science* **1947**, *106*, 417.
158. Rebstock, M.C.; Crooks, H.M.; Controulis, J.; et al. Chloramphenicol (Chloromycetin). ¹ IV.^{1a} Chemical Studies. *J. Am. Chem. Soc.* **1949**, *71*, 2458–2462.
159. Aronoff, D.M. Mildred Rebstock: Profile of the medicinal chemist who synthesized chloramphenicol. *Antimicrob. Agents Chemother.* **2019**, *63*, e00648-19.
160. Gaudelli, N.M.; Long, D.H.; Townsend, C.A. β -Lactam formation by a non-ribosomal peptide synthetase during antibiotic biosynthesis. *Nature* **2015**, *520*, 383–387.
161. Stapley, E.O.; Jackson, M.; Hernandez, S.; et al. Cephamycins, a new family of beta-lactam antibiotics. I. Production by actinomycetes, including *Streptomyces lactamdurans* sp. n. *Antimicrob. Agents Chemother.* **1972**, *2*, 122–131.
162. Onishi, H.R.; Daoust, D.R.; Zimmerman, S.B.; et al. Cefoxitin, a semisynthetic cephamycin antibiotic: Resistance to beta-lactamase inactivation. *Antimicrob. Agents Chemother.* **1974**, *5*, 38–48.
163. Karady, S.; Pines, S.H.; Weinstock, L.M.; et al. Semisynthetic cephalosporins via a novel acyl exchange reaction. *J. Am. Chem. Soc.* **1972**, *94*, 1410–1411.
164. Rolinson, G.N. Evolution of beta-lactamase inhibitors. *Rev. Infect. Dis.* **1991**, *13*, S727–S732.
165. Fisher, J.; Charnas, R.L.; Knowles, J.R. Kinetic studies on the inactivation of *Escherichia coli* RTEM beta-lactamase by clavulanic acid. *Biochemistry* **1978**, *17*, 2180–2184.
166. Ball, A.P.; Geddes, A.M.; Davey, P.G.; et al. Clavulanic acid and amoxycillin: A clinical, bacteriological, and pharmacological study. *Lancet* **1980**, *1*, 620–623.
167. White, A.R.; Kaye, C.; Poupard, J.; et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: A review of the continuing development of an innovative antimicrobial agent. *J. Antimicrob. Chemother.* **2004**, *53*, i3–i20.
168. Li, R.; Khaleeli, N.; Townsend, C.A. Expansion of the clavulanic acid gene cluster: Identification and *in vivo* functional analysis of three new genes required for biosynthesis of clavulanic acid by *Streptomyces clavuligerus*. *J. Bacteriol.* **2000**, *182*, 4087–4095.
169. Song, J.Y.; Jensen, S.E.; Lee, K.J. Clavulanic acid biosynthesis and genetic manipulation for its overproduction. *Appl. Microbiol. Biotechnol.* **2010**, *88*, 659–669.
170. Paradkar, A. Clavulanic acid production by *Streptomyces clavuligerus*: Biogenesis, regulation and strain improvement. *J. Antibiot.* **2013**, *66*, 411–420.
171. Gong, J.; Yi, J.S.; An, S.; et al. Integrated genomic-transcriptomic analysis of clavulanic acid production in differentially productive *Streptomyces clavuligerus* strains. *Sci. Rep.* **2025**, *15*, 45495.
172. Liras, P.; Gomez-Escribano, J.P.; Santamarta, I. Regulatory mechanisms controlling antibiotic production in *Streptomyces clavuligerus*. *J. Ind. Microbiol. Biotechnol.* **2008**, *35*, 667–676.
173. Salowe, S.P.; Marsh, E.N.; Townsend, C.A. Purification and characterization of clavaminic synthase from *Streptomyces clavuligerus*: An unusual oxidative enzyme in natural product biosynthesis. *Biochemistry* **1990**, *29*, 6499–6508.
174. Tally, F.P.; Jacobus, N.V.; Gorbach, S.L. *In vitro* activity of N-formimidoyl thienamycin (MK0787). *Antimicrob. Agents Chemother.* **1980**, *18*, 642–644.
175. Kahan, F.M.; Kropp, H.; Sundelof, J.G.; et al. Thienamycin: Development of imipenem-cilastatin. *J. Antimicrob. Chemother.* **1983**, *12*, 1–35.
176. Zhanel, G.G.; Simor, A.E.; Vercaigne, L.; et al. Imipenem and meropenem: Comparison of *in vitro* activity, pharmacokinetics, clinical trials and adverse effects. *Can. J. Infect. Dis.* **1998**, *9*, 215–228.
177. Kropp, H.; Sundelof, J.G.; Hajdu, R.; et al. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. *Antimicrob. Agents Chemother.* **1982**, *22*, 62–70.
178. Norrby, S.R.; Alestig, K.; Ferber, F.; et al. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. *Antimicrob. Agents Chemother.* **1983**, *23*, 293–299.
179. Nunez, L.E.; Mendez, C.; Brana, A.F.; et al. The biosynthetic gene cluster for the beta-lactam carbapenem thienamycin in *Streptomyces cattleya*. *Chem. Biol.* **2003**, *10*, 301–311.
180. Waksman, S.A.; Reilly, H.C.; Johnstone, D.B. Isolation of Streptomycin-producing Strains of *Streptomyces griseus*. *J. Bacteriol.* **1946**, *52*, 393–397.
181. Ball, S.; Bessell, C.J.; Mortimer, A. The production of polyenic antibiotics by soil streptomycetes. *J. Gen. Microbiol.* **1957**, *17*, 96–103.
182. Routien, J.B. Distribution of streptomycetes that produce antibiotics. *J. Bacteriol.* **1961**, *81*, 218–225.

183. Chan, E.; Martelli, P.; Hui, S.W.; et al. *In vitro* susceptibility of ceftolozane-tazobactam against *Burkholderia pseudomallei*. *Antimicrob. Agents Chemother.* **2018**, *62*, e00103-18.
184. Chan, E.; Wu, A.K.L.; Tse, C.W.S.; et al. *In vitro* susceptibility of *Salmonella enterica* serovar Typhi to ceftolozane/tazobactam. *J. Antimicrob. Chemother.* **2019**, *74*, 528–530.
185. Teng, J.L.L.; Chan, E.; Dai, A.C.H.; et al. *In vitro* susceptibility of typhoidal, nontyphoidal, and extended-spectrum-beta-lactamase-producing *Salmonella* to ceftolozane/tazobactam. *Antimicrob. Agents Chemother.* **2022**, *66*, e0122421.
186. Teng, J.L.L.; Chan, E.; Li, T.T.; et al. Antibiotic susceptibility of aerobic and facultative anaerobic Gram-negative rods in Hong Kong and implications on usefulness of ceftazidime-avibactam and ceftolozane-tazobactam. *Antibiotics* **2024**, *13*, 802.
187. Hannigan, G.D.; Prihoda, D.; Palicka, A.; et al. A deep learning genome-mining strategy for biosynthetic gene cluster prediction. *Nucleic Acids Res.* **2019**, *47*, e110.
188. Woo, P.C.Y. Rigorous analysis of microbes and infectious diseases using an expanding range of robust in silico technologies. *eMicrobe* **2025**, *1*, 1.
189. Frishman, D. From petri dishes to algorithms: The role of AI in modern microbiology. *eMicrobe* **2025**, *1*, 7.
190. Nahar, L. In silico technologies advancing microbial science: A visionary review. *eMicrobe* **2026**, *2*, 4.